BACKGROUND: The safety, tolerability, and immunogenicity of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% (dual-vial unit of human immunoglobulin 10% and recombinant human hyaluronidase [rHuPH20]) were assessed in children with primary immunodeficiency diseases (PIDs). METHODS: This phase 4, post-authorization, prospective, interventional, multicenter study (NCT03116347) conducted in the European Economic Area, enrolled patients aged 2 to < 18 years with a documented PID diagnosis who had received immunoglobulin therapy for ≥ 3 months before enrollment. New fSCIG 10% starters underwent fSCIG 10% dose ramp-up for ≤ 6 weeks (epoch 1) before receiving fSCIG 10% for ≤ 3 years (epoch 2); patients pretreated with fSCIG 10% entered epoch 2 directly. The primary outcome was the number and rate (per infusion) of all noninfectious treatment-related serious and severe adverse events (AEs). RESULTS: In total, 42 patients were enrolled and dosed (median [range] age: 11.5 [3-17] years; 81% male; 23 new starters; 19 pretreated). Overall, 49 related noninfectious, treatment-emergent AEs (TEAEs) were reported in 15 patients; most were mild in severity (87.8%). No treatment-related serious TEAEs were reported. Two TEAEs (infusion site pain and emotional distress) were reported as severe and treatment-related in a single new fSCIG 10% starter. The rate of local TEAEs was lower in pretreated patients (0.1 event/patient-year) versus new starters (1.3 events/patient-year). No patients tested positive for binding anti-rHuPH20 antibodies (titer of ≥ 1:160). CONCLUSIONS: No safety signals were identified, and the incidence of local AEs declined over the duration of fSCIG 10% treatment. This study supports fSCIG 10% long-term safety in children with PIDs. TRIAL REGISTRATION NUMBER (CLINICALTRIALS.GOV): NCT03116347.

Baxalta Innovations GmbH a Takeda Company Vienna Austria

Centre for Primary Immunodeficiencies Department of Pediatrics Jessenius Faculty of Medicine Comenius University in Bratislava University Hospital Martin Martin Slovakia

Department of Paediatric Immunology Bristol Royal Hospital for Children Bristol UK

Department of Paediatrics Faculty of Medicine Comenius University Bratislava National Institute of Children's Diseases Bratislava Slovakia

Department of Pediatric Hematology and Stem Cell Transplantation Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases Budapest Hungary

Department of Pediatric Oncology Hematology and Immunology Skåne University Hospital Lund Sweden

Department of Pediatrics Faculty of Medicine Masaryk University Brno Czech Republic

Immunodeficiency Centre for Wales University Hospital of Wales Cardiff UK

Takeda Development Center Americas Inc Cambridge MA USA

University of California Irvine Irvine CA USA

Zobrazit více v PubMed

Yamashita M, Inoue K, Okano T, Morio T. Inborn errors of immunity—recent advances in research on the pathogenesis. Inflamm Regen. 2021;41(1):1–7. PubMed PMC

Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies. N Engl J Med. 1995;333(7):431–40. PubMed

McCusker C, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol. 2011;7(Suppl 1):S11. PubMed PMC

Gardulf A, Björvell H, Gustafson R, Hammarström L, Smith CI. Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency. Immunodeficiency. 1993;4(1–4):81–4. PubMed

Wasserman RL. Immunoglobulin replacement for primary immunodeficiency: indications for initiating and continuing treatment. Allergy Asthma Proc. 2021;42(6):489–94. PubMed

Nordin J, Solís L, Prévot J, Mahlaoui N, Chapel H, Sánchez-Ramón S, et al. The PID principles of care: where are we now? A global status report based on the PID Life Index. Front Immunol. 2021;12:780140. PubMed PMC

European Medicines Agency. HyQvia – Summary of product characteristics. Accessed June 2024. https://www.ema.europa.eu/en/documents/product-information/hyqvia-epar-product-information_en.pdf.

United States Food and Drug Administration. Prescribing information: HyQvia 100 mg/mL solution for infusion for subcutaneous use. Accessed June 2024. https://www.shirecontent.com/PI/PDFs/HYQVIA_USA_ENG.pdf.

Wasserman RL. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy. 2017;9(12):1035–50. PubMed

Wasserman RL, Melamed I, Kobrynski L, Puck J, Gupta S, Doralt J, et al. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability. Immunotherapy. 2016;8(10):1175–86. PubMed

Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31(3):323–31. PubMed

Wasserman RL, Melamed I, Stein MR, Engl W, Sharkhawy M, Leibl H, et al. Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency. J Clin Immunol. 2016;36(6):571–82. PubMed PMC

Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951–7. e11. PubMed

Niraj C, Patel J, Walter RL, Wasserman A, Rubinstein T, Prescott Atkinson M, Shepherd et al. Efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency disease. Clin Immunol. 2023;250(109598).

Jolles S, Orange J, Gardulf A, Stein M, Shapiro R, Borte M, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179(2):146–60. PubMed PMC

von Achenbach C, Hevia Hernandez G, von Gunten S. The choice between intravenous and subcutaneous immunoglobulins: aspects for consideration. Pharmacology. 2022;107(11–12):556–63. PubMed

Kanegane H, Imai K, Yamada M, Takada H, Ariga T, Bexon M, et al. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases. J Clin Immunol. 2014;34:204–11. PubMed PMC

Milota T, Bloomfield M, Kralickova P, Jilek D, Novak V, Litzman J, et al. Czech Hizentra noninterventional study with rapid push: efficacy, safety, tolerability, and convenience of therapy with 20% subcutaneous immunoglobulin. Clin Ther. 2019;41(11):2231–8. PubMed

Frenzel W, Wietek S, Svae T-E, Debes A, Svorc D. Tolerability and safety of Octagam®(IVIG): a post-authorization safety analysis of four non-interventional phase IV trials. Int J Clin Pharmacol Ther. 2016;54(11):847–55. PubMed PMC

Stein MR, Nelson RP, Church JA, Wasserman RL, Borte M, Vermylen C, et al. Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29:137–44. PubMed

Krivan G, Chernyshova L, Kostyuchenko L, Lange A, Nyul Z, Derfalvi B, et al. A multicentre study on the efficacy, safety and pharmacokinetics of IqYmune®, a highly purified 10% liquid intravenous immunoglobulin, in patients with primary immune deficiency. J Clin Immunol. 2017;37:539–47. PubMed PMC

Beydoun SR, Sharma KR, Bassam BA, Pulley MT, Shije JZ, Kafal A. Individualizing therapy in CIDP: a mini-review comparing the pharmacokinetics of ig with SCIg and IVIg. Front Neurol. 2021;12:638816. PubMed PMC

Wasserman RL, Gupta S, Stein M, Rabbat CJ, Engl W, Leibl H, et al. Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases. Immunotherapy. 2022;14(4):215–24. PubMed

Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29:173–84. PubMed

Baumann U, Fasshauer M, Pausch C, Wittkowski H, Hermann C, Pittrow D, et al. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases. Immunotherapy. 2022;14(2):135–43. PubMed

Mallick R, Solomon G, Bassett P, Zhang X, Patel P, Lepeshkina O. Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes. Allergy Asthma Clin Immunol. 2022;18(1):1–20. PubMed PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03116347